Literature DB >> 21256140

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.

Adam L Halberstadt1, Mark A Geyer.   

Abstract

Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT(2) receptor agonists, whereas the indoleamines are relatively non-selective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the characteristic effects of hallucinogens are mediated by interactions with the 5-HT(2A) receptor. Nevertheless, there is also evidence that interactions with other receptor sites contribute to the psychopharmacological and behavioral effects of the indoleamine hallucinogens. This article reviews the evidence demonstrating that the effects of indoleamine hallucinogens in a variety of animal behavioral paradigms are mediated by both 5-HT(2) and non-5-HT(2) receptors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21256140      PMCID: PMC3110631          DOI: 10.1016/j.neuropharm.2011.01.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  268 in total

1.  Comparison of psilocin with psilocybin, mescaline and LSD-25.

Authors:  A B WOLBACH; E J MINER; H ISBELL
Journal:  Psychopharmacologia       Date:  1962

2.  1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.

Authors:  Thomas H McLean; Jason C Parrish; Michael R Braden; Danuta Marona-Lewicka; Alejandra Gallardo-Godoy; David E Nichols
Journal:  J Med Chem       Date:  2006-09-21       Impact factor: 7.446

3.  5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.

Authors:  J R Martin; M Bös; F Jenck; J Moreau; V Mutel; A J Sleight; J Wichmann; J S Andrews; H H Berendsen; C L Broekkamp; G S Ruigt; C Köhler; A M Delft
Journal:  J Pharmacol Exp Ther       Date:  1998-08       Impact factor: 4.030

4.  The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats.

Authors:  Kirsten Krebs-Thomson; Erbert M Ruiz; Virginia Masten; Mahalah Buell; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-30       Impact factor: 4.530

5.  A possible correlation between drug-induced hallucinations in man and a behavioural response in mice.

Authors:  S J Corne; R W Pickering
Journal:  Psychopharmacologia       Date:  1967

6.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.

Authors:  R J Strassman; C R Qualls
Journal:  Arch Gen Psychiatry       Date:  1994-02

8.  Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.

Authors:  D G Grahame-Smith
Journal:  J Neurochem       Date:  1971-06       Impact factor: 5.372

9.  Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding.

Authors:  M Pompeiano; J M Palacios; G Mengod
Journal:  J Neurosci       Date:  1992-02       Impact factor: 6.167

10.  A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine.

Authors:  S J CORNE; R W PICKERING; B T WARNER
Journal:  Br J Pharmacol Chemother       Date:  1963-02
View more
  80 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

Review 3.  Alternative drugs of abuse.

Authors:  M E Sutter; J Chenoweth; T E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

Review 4.  Plant-based medicines for anxiety disorders, part 2: a review of clinical studies with supporting preclinical evidence.

Authors:  Jerome Sarris; Erica McIntyre; David A Camfield
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

5.  Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.

Authors:  Adam L Halberstadt; Mark A Geyer
Journal:  Neuropharmacology       Date:  2013-09-04       Impact factor: 5.250

Review 6.  Licit and illicit drug use in cluster headache.

Authors:  Amelie Govare; Elizabeth Leroux
Journal:  Curr Pain Headache Rep       Date:  2014-05

7.  Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Authors:  Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2018-09-25       Impact factor: 5.858

8.  Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Pharmacol Rep       Date:  2016-02-05       Impact factor: 3.024

9.  Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives.

Authors:  Simon D Brandt; Pierce V Kavanagh; Geraldine Dowling; Brian Talbot; Folker Westphal; Markus R Meyer; Hans H Maurer; Adam L Halberstadt
Journal:  Drug Test Anal       Date:  2016-04-21       Impact factor: 3.345

Review 10.  Lysergic acid diethylamide: a drug of 'use'?

Authors:  Saibal Das; Preeti Barnwal; Anand Ramasamy; Sumalya Sen; Somnath Mondal
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.